Charles River Laboratories opened lower at $372.99, compared with its previous close of $376.10. In the last trading session, the stock traded between $352.54 and $374.56. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Charles River Laboratories is now worth
$ 79.12
resulting in a loss of
$ 20.88 (20.88%)
Note: Past profits do not guarantee future returns.
Rating from 14 Analysts
Today's Change
$-21.10 (-5.61%)
Day High
$374.56
Day Low
$352.54
Day Open
$372.99
Prev Close
$376.10
Volume
7,07,073
1W Return
4.48%
1M Return
19.89%
3M Return
51.10%
6M Return
116.68%
1Y Return
97.06%
Market Cap ($ Mn)
16,947
PE Ratio
-
PB Ratio
4.90
PEG Ratio
-
ROE
-4.29%
ROCE
0.04%
EPS (TTM)
$-0.03
1 Week
4.48%
1 Month
19.89%
3 Months
51.10%
6 Months
116.68%
9 Months
67.71%
Charles River Laboratories delivers 17.1% annualized return over 15 years
Charles River Laboratories delivered an average annual return of 17.1% over the last 15 years. A $1,000 investment from 15 years ago is now valued at $11,204.35. The company outperformed the market by 4.33% on an annualized basis. Current market capitalization stands at $15.34 billion.
8 days agoCharles River Laboratories delivers 10.15% annualized return over 20 years
Charles River Laboratories delivered an average annual return of 10.15% over the last 20 years. The stock outperformed the market by 1.14% on an annualized basis during this period. A $1,000 investment made 20 years ago is now valued at $6,918.09. Current market capitalization stands at $15.44 billion with a share price of $301.62.
16 days agoCharles River Labs partners with Magellan for stem cell therapy development
Charles River Laboratories International partners with Australian biotech firm Magellan Stem Cells. Collaboration focuses on developing and clinically advancing stem cell-based therapies. Services include biologics quality control, cGMP viral testing, and release testing. Partnership aims to integrate development support with Magellan’s cell therapy manufacturing.
17 days agoCharles River Labs and Autolomous launch Apollo Orchestrate for lab digitization
Launches Apollo Orchestrate to digitize laboratory execution. Integrates Autolomous autoloMATE with Charles River Apollo platform. Targets Biologics Testing Solutions sites in North America and Europe. Supports GMP quality control testing with digital traceability.
24 days agoCharles River Labs reiterates FY26 outlook, targets 5-7% growth by 2030
Reiterates FY26 organic revenue growth at upper end of 0-1%. Sets 2027-2030 organic revenue CAGR target at 5-7%. Targets ~24% non-GAAP operating margin by 2030, up from 21.0-21.3% in FY26. Guides FY26 non-GAAP EPS to upper end of $11.15-$11.45.
1mo agoCharles River, Medigen partner on enterovirus vaccine development
Charles River Laboratories and Medigen Vaccine Biologics are collaborating on the CMC activities for Medigen's next-generation multivalent enterovirus vaccine. Using NGS technology, Charles River will help validate the virus seed bank to support IND applications and global regulatory compliance. The deal builds on Medigen's prior success with its ENVACGEN vaccine approved in Taiwan and Vietnam.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $252.92 | +2.97% | $27,826.01M | 25.77 | |
| $185.31 | +1.49% | $24,867.86M | - |
An investment of $100 made 5 years ago in Charles River Laboratories is now worth
$ 79.12
resulting in a loss of
$ 20.88 (20.88%)
Note: Past profits do not guarantee future returns.
